← back to search

Mineo Kurokawa

Nagasaki University · JP
Area of research
Hematology · Pathology and Forensic Medicine
Research interest
Research interests include Acute Myeloid Leukemia Research, Hematopoietic Stem Cell Transplantation, Chronic Myeloid Leukemia Treatments, and Lymphoma Diagnosis and Treatment.
h-index
68
citations
19,815
works
835
NIH funding
primary concept
Medicine
email

Recent publications

Genome-wide screening identifies ZFP91 as a key regulator of EVI1 in myeloid leukemia.
2026cited by 0position: contributordoi
Successful treatment of type I cryoglobulinemia with a combination of carfilzomib, cyclophosphamide, and dexamethasone: a case report and literature review.
2025cited by 0position: contributordoi
Prognostic impact of effusion in multiple body cavities after allogeneic hematopoietic stem cell transplantation.
2025cited by 0position: contributordoi
Discovery of a second, distinct development pattern of leukemic conversion from paroxysmal nocturnal hemoglobinuria.
2025cited by 0position: contributordoi
Prognostic factors of idiopathic hypereosinophilic syndrome: A nationwide survey in Japan.
2024cited by 3position: contributordoi
Adult T-cell leukemia-lymphoma with neurolymphomatosis successfully controlled by valemetostat: a case report and review of literature.
2024cited by 0position: contributordoi
Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in <i>RUNX1</i>, <i>GATA2</i>, and <i>DDX41</i>
Blood Advances 2023cited by 37position: middledoi
Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41.
2023cited by 30position: contributordoi
EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment
Blood Advances 2023cited by 17position: contributordoi
Myeloid sarcoma and pathological fracture: a case report and review of literature.
2023cited by 4position: contributordoi
Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma.
2023cited by 2position: contributordoi
Daratumumab plus lenalidomide and dexamethasone for relapsed POEMS syndrome with bone plasmacytoma harboring 17p deletion.
2023cited by 2position: contributordoi
Isolated relapse of plasma cell leukemia in the central nervous systems: a case report and literature review.
2023cited by 1position: contributordoi
Acute pancreatitis as the initial manifestation of acute myeloid leukemia with chromosome 16 rearrangements.
2023cited by 0position: contributordoi
Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis.
2023cited by 0position: contributordoi
Expansion of large granular lymphocytes after autologous hematopoietic stem cell transplantation.
2023cited by 0position: contributordoi
Development of Epstein-Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma.
2023cited by 0position: contributordoi
Inherited macrothrombocytopenia due to a novel splice donor site mutation in ITGB3.
2023cited by 0position: contributordoi
Independent origins of fetal liver haematopoietic stem and progenitor cells
Nature 2022cited by 160position: middledoi
Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis.
2022cited by 11position: contributordoi
Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in <i>RUNX1</i>, <i>GATA2</i> and <i>DDX41</i>
Blood 2022cited by 6position: middledoi
CCDC88C-FLT3 gene fusion in CD34-positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia.
2022cited by 5position: contributordoi
Reduced bendamustine for elderly patients with follicular lymphoma.
2022cited by 3position: contributordoi
Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab.
2022cited by 2position: contributordoi
Severe infections and renal dysfunction during immunosuppressive therapy with cyclosporine A for aplastic anemia.
2022cited by 1position: contributordoi
Clinical usefulness of a novel classification of T cell distribution patterns in the tumor microenvironment of follicular lymphoma to detect transformation.
2022cited by 1position: contributordoi
Risk of febrile neutropenia in very elderly patients aged ≥80 years receiving their first cycle of R-CHOP regimen: a nationwide real-world study in Japan.
2022cited by 1position: contributordoi
A case of JAK2 V617F positive essential thrombocythemia successfully controlled by imatinib mesylate.
2022cited by 0position: contributordoi
Successful diagnosis of veno-occlusive disease caused by inotuzumab ozogamicin through minimal-invasive angiography: a case report.
2022cited by 0position: contributordoi
R-GCD regimen in elderly patients with relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma: a retrospective single-center analysis.
2022cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 38 papers (2019–2026)Toshio Suda · National Clinical Research3 papers (2015–2022)Tomomasa Yokomizo · National University of Singapore2 papers (2019–2022)Yosuke Masamoto · Springer Nature2 papers (2023–2026) · 2 papers (2019–2022) · 2 papers (2019–2022)Motomi Osato · National University of Singapore2 papers (2019–2022) · 1 papers (2012–2012)Martin M. Riccomagno · University of California, Riverside1 papers (2014–2014) · 1 papers (2019–2019)Akiko Saito · Nagoya University Hospital1 papers (2024–2024)Florian Richter · Technische Hochschule Mannheim1 papers (2012–2012) · 1 papers (2022–2022)Aaron M. Goodman · Moores Cancer Center1 papers (2020–2020) · 1 papers (2015–2015) · 1 papers (2022–2022)Julien Haroche · Laboratoire National de Référence1 papers (2020–2020)Kazuhiro Toyama · Seirei Sakura Citizen Hospital1 papers (2020–2020)R. Yu · Novartis (Switzerland)1 papers (2012–2012)Kimiyo N. Yamamoto · Harvard Stem Cell Institute1 papers (2015–2015)